Pharmacology in IR and IH

Pharmacology in IR and IH — Expert Level

How it begins

Farmacocinética aplicada a la disfunción orgánica: mecanismos de alteración, estrategias de ajuste de dosis, monitorización terapéutica y correlaciones clínicas en los órganos de eliminación farmacológica.

What it covers

1. PK in IR and IH
2. 01 Introduction: The Pharmacological Problem
3. · 1.1 Clinical Impact of Organ Dysfunction on PK
4. 02 Pharmacokinetics: Essential Concepts for IR/IH
5. · 2.1 Clearance Total
6. · 2.2 Half-life (t½) and Steady State in Organic Dysfunction
7. · 2.3 Effect of the First Hepatic Pass on IH
8. · 2.4 Binding to Plasma Proteins
9. 03 Renal Physiology and Classification of IR
10. · 3.1 Kidney Functions with Pharmacological Impact
11. · 3.2 KDIGO Classification of CKD (Staging)
12. · 3.3 IRA vs. CKD — Pharmacological Differences
13. 04 Impact of IR on Pharmacokinetics
14. · 4.1 Accumulation of Active Metabolites
15. 05 Evaluation of Kidney Function for Dosage
16. · 5.1 Serum Creatinine — Its Limitations
17. · 5.2 TFG Estimation Formulas
18. · 5.3 Emerging Biomarkers of Kidney Function
19. 06 Principles of Dose Adjustment in IR
20. · 6.1 Dose Adjustment Method
21. · 6.2 Loading Dose
22. · 6.3 Reference Sources for Dose Adjustment in IR
23. 07 Drugs of Special Relevance in IR
24. · 7.1 Antibiotics
25. · 7.2 Analgesics in IR
26. · 7.3 Cardiovascular Drugs in IR
27. · 7.4 Other Critical Drugs in IR
28. 08 Dialysis and Pharmacokinetics
29. · 8.1 Factors that Determine Dialyzability
30. · 8.2 Classification of Drugs by Dialyzability
31. · 8.3 Continuous Hemofiltration (VVCHDF/CVVHDF)
32. 09 Pharmacological Nephrotoxicity
33. 10 Liver Physiology and Classification of IH
34. · 10.1 Liver Functions with Pharmacological Impact
35. · 10.2 Child-Pugh Classification
36. · 10.3 MELD Score
37. 11 Impact of HI on Pharmacokinetics
38. · 11.1 The Concept of Liver Extraction Ratio (E H )
39. 12 Pharmacological Evaluation of Liver Function
40. · 12.1 Limitations of Standard Liver Tests
41. · 12.2 Specific Liver Function Tests for PK
42. · 12.3 Practical Guide to Adjustment in IH according to Child-Pugh
43. 13 Principles of Dose Adjustment in IH
44. · 13.1 Practical Adjustment Rules
45. 14 Drugs of Special Relevance in IH
46. · 14.1 Complete IH Adjustment Table
47. · 14.2 Sedation in IH — Management of the Cirrhotic Patient
48. 15 Pharmacological Hepatotoxicity (DILI)
49. · 15.1 DILI Mechanistic Classification
50. · 15.2 DILI Biochemical Patterns (DILI Network / CIOMS Criteria)
51. · 15.3 Drugs with Hepatotoxicity of High Clinical Relevance
52. 16 Simultaneous IR + IH — The Most Complex Scenario
53. · 16.1 Hepatorrenal Syndrome (HRS)
54. · 16.2 Principles of Prescription in Biorganic Failure
55. 17 Therapeutic Pharmacological Monitoring (TDM)
56. · 17.1 Drugs with TDM Standard in IR/IH
57. 18 Special Populations with IR/IH
58. · 18.1 Elderly Patient with IR/IH
59. · 18.2 Oncology Patient with IR/IH
60. · 18.3 Kidney and Liver Transplantation — Posttransplant Pharmacology